PTG depletion removes lafora bodies and rescues the fatal epilepsy of lafora disease

PLoS Genetics

Volumn 7, Issue 4, 2011, Pages

  Turnbull, Julie ^a,b   DePaoli Roach, Anna A ^c   Zhao, Xiaochu ^a   Cortez, Miguel A ^a   Pencea, Nela ^a   Tiberia, Erica ^a   Piliguian, Mark ^a   Roach, Peter J ^c   Wang, Peixiang ^a   Ackerley, Cameron A ^a   Minassian, Berge A ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE DERIVATIVE; GLYCOGEN; GLYCOGEN SYNTHASE; GLYCOSYLTRANSFERASE INHIBITOR; PHOSPHOPROTEIN PHOSPHATASE 1; POLYGLUCOSAN; PROTEIN TARGETING TO GLYCOGEN; UNCLASSIFIED DRUG; GLUCAN; PPP1R3C PROTEIN, MOUSE; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE INACTIVATION; MOUSE; MYOCLONUS EPILEPSY; NERVE DEGENERATION; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN TARGETING; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY;

MUS;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GLUCANS; GLYCOGEN SYNTHASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LAFORA DISEASE; MICE; MICE, KNOCKOUT;

EID: 79955634506     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002037     Document Type: Article

References (46)

1. Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, et al. (2003) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 35: 125-127.
2. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, et al. (1998) Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 20: 171-174.
3. Cavanagh JB, (1999) Corpora-amylacea and the family of polyglucosan diseases. Brain Res Brain Res Rev 29: 265-295.
4. Lafora GR, Glueck B, (1911) Beitrag zur Histopathologie der myoklonischen Epilepsie. Zeitschrift Gesamte Neurologische Psychiatrie 6: 1-14.
5. Minassian BA, (2001) Lafora's disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 25: 21-29.
6. Van Heycop Ten Ham M, (1975) Lafora disease, a form of progressive myoclonus epilepsy. In: Vinken PJBG, editors. The epilepsies; Handbook of clinical neurology Amsterdam Elsevier pp. 382-422.
7. Graham TE, Yuan Z, Hill AK, Wilson RJ, (2010) The regulation of muscle glycogen: the granule and its proteins. Acta Physiol (Oxf) 199: 489-498.
8. Hejazi M, Fettke J, Haebel S, Edner C, Paris O, et al. (2008) Glucan, water dikinase phosphorylates crystalline maltodextrins and thereby initiates solubilization. Plant J 55: 323-334.
9. Sakai M, Austin J, Witmer F, Trueb L, (1970) Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 20: 160-176.
10. Fong NM, Jensen TC, Shah AS, Parekh NN, Saltiel AR, et al. (2000) Identification of binding sites on protein targeting to glycogen for enzymes of glycogen metabolism. J Biol Chem 275: 35034-35039.
11. Printen JA, Brady MJ, Saltiel AR, (1997) PTG, a protein phosphatase 1-binding protein with a role in glycogen metabolism. Science 275: 1475-1478.
12. Fernandez-Sanchez ME, Criado-Garcia O, Heath KE, Garcia-Fojeda B, Medrano-Fernandez I, et al. (2003) Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet 12: 3161-3171.
13. Vilchez D, Ros S, Cifuentes D, Pujadas L, Valles J, et al. (2007) Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 10: 1407-1413.
14. Worby CA, Gentry MS, Dixon JE, (2008) Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J Biol Chem 283: 4069-4076.
15. DePaoli-Roach AA, Tagliabracci VS, Segvich DM, Meyer CM, Irimia JM, et al. (2010) Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin. J Biol Chem 285: 25372-25381.
16. Tagliabracci VS, Girard JM, Segvich D, Meyer C, Turnbull J, et al. (2008) Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J Biol Chem 283: 33816-33825.
17. Turnbull J, Wang PX, Girard JM, Ruggieri A, Wang TJ, et al. (2010) Glycogen hyperphosphorylation underlies Lafora Body formation. Ann Neurol Epub Oct 28.
18. Tagliabracci VS, Turnbull J, Wang W, Girard JM, Zhao X, et al. (2007) Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Natl Acad Sci U S A 104: 19262-19266.
19. Worby CA, Gentry MS, Dixon JE, (2006) Laforin, a dual specificity phosphatase that dephosphorylates complex carbohydrates. J Biol Chem 281: 30412-30418.
20. Pederson BA, Cope CR, Schroeder JM, Smith MW, Irimia JM, et al. (2005) Exercise capacity of mice genetically lacking muscle glycogen synthase: in mice, muscle glycogen is not essential for exercise. J Biol Chem 280: 17260-17265.
21. Pederson BA, Chen H, Schroeder JM, Shou W, DePaoli-Roach AA, et al. (2004) Abnormal cardiac development in the absence of heart glycogen. Mol Cell Biol 24: 7179-7187.
22. Crosson SM, Khan A, Printen J, Pessin JE, Saltiel AR, (2003) PTG gene deletion causes impaired glycogen synthesis and developmental insulin resistance. J Clin Invest 111: 1423-1432.
23. Zhai L, Choi CS, Irimia-Dominguez J, Mcguire AC, Kim S, et al. (2007) Enhanced Insulin Sensitivity and Energy Expenditure in PPP1R3C (PTG) Deleted Mice. Diabetes 56: A62.
24. Ganesh S, Delgado-Escueta AV, Sakamoto T, Avila MR, Machado-Salas J, et al. (2002) Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet 11: 1251-1262.
25. Crompton DE, Berkovic SF, (2009) The borderland of epilepsy: clinical and molecular features of phenomena that mimic epileptic seizures. Lancet Neurol 8: 370-381.
26. Yokoi F, Dang MT, Li J, Li Y, (2006) Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice. J Biochem 140: 141-146.
27. Lohi H, Young EJ, Fitzmaurice SN, Rusbridge C, Chan EM, et al. (2005) Expanded repeat in canine epilepsy. Science 307: 81.
28. Ceulemans H, Bollen M, (2004) Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev 84: 1-39.
29. Yokoi S, Austin J, Witmer F, Sakai M, (1968) Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases. Arch Neurol 19: 15-33.
30. Garyali P, Siwach P, Singh PK, Puri R, Mittal S, et al. (2009) The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system. Hum Mol Genet 18: 688-700.
31. Rao SN, Maity R, Sharma J, Dey P, Shankar SK, et al. (2010) Sequestration of chaperones and proteasome into Lafora bodies and proteasomal dysfunction induced by Lafora disease-associated mutations of malin. Hum Mol Genet 19: 4726-4734.
32. Vernia S, Rubio T, Heredia M, Rodriguez de Cordoba S, Sanz P, (2009) Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. PLoS One 4: e5907 doi:10.1371/journal.pone.0005907.
33. Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, et al. (2010) Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Hum Mol Genet 19: 2867-2876.
34. Lossos A, Meiner Z, Barash V, Soffer D, Schlesinger I, et al. (1998) Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol 44: 867-872.
35. Robitaille Y, Carpenter S, Karpati G, DiMauro SD, (1980) A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing. Brain 103: 315-336.
36. Kelker MS, Page R, Peti W, (2009) Crystal structures of protein phosphatase-1 bound to nodularin-R and tautomycin: a novel scaffold for structure-based drug design of serine/threonine phosphatase inhibitors. J Mol Biol 385: 11-21.
37. Baskaran S, Roach PJ, DePaoli-Roach AA, Hurley TD, (2010) Structural basis for glucose-6-phosphate activation of glycogen synthase. Proc Natl Acad Sci U S A 107: 17563-17568.
38. Horcajada C, Guinovart JJ, Fita I, Ferrer JC, (2006) Crystal structure of an archaeal glycogen synthase: insights into oligomerization and substrate binding of eukaryotic glycogen synthases. J Biol Chem 281: 2923-2931.
39. Barford D, Johnson LN, (1989) The allosteric transition of glycogen phosphorylase. Nature 340: 609-616.
40. Goldsmith EJ, Sprang SR, Hamlin R, Xuong NH, Fletterick RJ, (1989) Domain separation in the activation of glycogen phosphorylase a. Science 245: 528-532.
41. Lowe ED, Noble ME, Skamnaki VT, Oikonomakos NG, Owen DJ, et al. (1997) The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. EMBO J 16: 6646-6658.
42. Bruno C, van Diggelen OP, Cassandrini D, Gimpelev M, Giuffre B, et al. (2004) Clinical and genetic heterogeneity of branching enzyme deficiency (glycogenosis type IV). Neurology 63: 1053-1058.
43. van der Ploeg AT, Reuser AJ, (2008) Pompe's disease. Lancet 372: 1342-1353.
44. Douillard-Guilloux G, Raben N, Takikita S, Ferry A, Vignaud A, et al. (2010) Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum Mol Genet 19: 684-696.
45. Kollberg G, Tulinius M, Gilljam T, Ostman-Smith I, Forsander G, et al. (2007) Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med 357: 1507-1514.
46. Weibel ER, (1979) Point counting methods. In: Weibel ER, editors. Stereological Methods, Practical Methods for Biological Morphometry London Academic Press pp. 101-159.